<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083017</url>
  </required_header>
  <id_info>
    <org_study_id>RAHyCOstudy</org_study_id>
    <secondary_id>33CM30‚Äê124087</secondary_id>
    <secondary_id>CER09-237</secondary_id>
    <nct_id>NCT01083017</nct_id>
  </id_info>
  <brief_title>Resistant Arterial Hypertension Cohort Study</brief_title>
  <acronym>RAHyCo</acronym>
  <official_title>Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the epidemiology of resistant hypertension,
      evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the
      randomization of two doses of the diuretic used - chlorthalidone), study two interventions in
      the group of patients that is non-compliant, and study environmental and genetic variables of
      individuals with resistant hypertension in a family design.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>blood pressure control</measure>
    <time_frame>at 12 weeks after initiation of standard treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular morbidity and mortality</measure>
    <time_frame>5 years</time_frame>
    <description>additional secondary: BP control at yearly follow-up</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <condition>Essential Hypertension</condition>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>chlorthalidone</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>motivational invervention</arm_group_label>
    <description>motivational interview(s) vs. repeated calls vs. no particular intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standardized anti-hypertensive treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chlorthalidone</intervention_name>
    <description>chlorthalidone 25mg/d vs. chlorthalidone 50mg/d</description>
    <arm_group_label>chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>motivational intervention for non-compliant individuals</intervention_name>
    <description>motivational interview(s) vs. repeated calls vs. no particular intervention</description>
    <arm_group_label>motivational invervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standardized anti-hypertensive treatment</intervention_name>
    <description>olmesartan, amlodipine, chlorthalidone, +- spironolactone</description>
    <arm_group_label>standardized anti-hypertensive treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, DNA, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients addressed to a speciality consultation at Geneva University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  resistant hypertension at the moment of inclusion

          -  18 years or more, both sexes are included

          -  women at reproductive age: consenting to use oral contraception

        Exclusion Criteria:

          -  patients mentally impaired or unable to give informed consent

          -  patients speaking only a foreign language other than French, German, or English

          -  patients living far away, making the study visits not practical
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoinette PECHERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geneva University Hospitals, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg B EHRET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geneva University Hospitals, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg B EHRET, MD</last_name>
    <phone>011-41-22-7920322</phone>
    <email>georg@rhone.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geneva University Hospitals</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg B EHRET, MD</last_name>
      <phone>011-41-22-3723311</phone>
      <email>georg@rhone.ch</email>
    </contact>
    <contact_backup>
      <last_name>Antoinette PECHERE, MD</last_name>
      <phone>011-41-22-3723311</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital, CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregoire Wuerzner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Erne, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Georg EHRET</investigator_full_name>
    <investigator_title>intern</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

